Medical Oncology Department, Hospital Universitario Puerta del Mar (HUPM), Ana de Viya 21, 11009, Cádiz, Spain.
Instituto de Investigación e Innovación Biomédica de Cádiz (INIBiCA) [Institute for Biomedica Research and Innovation], Ana de Viya 21, 11009, Cádiz, Spain.
Sci Rep. 2023 May 3;13(1):7168. doi: 10.1038/s41598-023-34429-9.
Adjuvant trastuzumab in HER2+ breast cancer reduces recurrence and mortality, and has been the standard treatment since 2006. The objective was to analyze health outcomes in the real world. Observational, retrospective study of patients with HER2+ breast cancer, stages I-III, treated with adjuvant trastuzumab in the past 15 years in only one center and for the first time in Spain. Survival was analyzed according to the number of cycles and cardiotoxicity. Two hundred and seventy-five HER2positive patients (18.60%) out of 1479 received adjuvant (73%) or neoadjuvant/adjuvant (26%) trastuzumab, concomitantly (90%) or sequentially (10%) with chemotherapy. The probability of overall and disease-free survival (OS and DFS) at 5 years was 0.93 (95% CI 0.89-0.96), and 0.88 (95% CI 0.83-0.92). The number of cases with a significant and asymptomatic decrease in ventricular ejection fraction and heart failure were 54 (19.64%) and 12 (4.36%), respectively. Sixty-eight patients (24.70%) received 16 or fewer cycles, especially those older than 65 (OR 0.371, 95% CI 0.152-0.903; p = 0.029) and with cardiotoxicity (OR 15.02, 95% CI 7.437-30.335; p < 0.001). The risk of cardiotoxicity was associated with having received radiotherapy (OR 0.0362, 95% CI 0.139-0.938; p = 0.037). Arterial hypertension (HR 0.361, 95% CI 0.151-0.863, p = 0.022), neoadjuvant treatment (HR 0.314, 95% CI 0.132-0.750, p = 0.009) and cardiotoxicity (HR 2.755, 95% CI 1.235-6.143, p = 0.013) maintained significant association with OS. Only neoadjuvant treatment maintained a significant association with DFS (HR 0.437, 95% CI 0.213-0.899, p = 0.024). The effectiveness of neoadjuvant and adjuvant trastuzumab can be considered comparable to those of clinical trials. In the real world, factors such as age, hypertension, radiotherapy, neoadjuvant treatment, and cardiotoxicity should be taken into consideration to optimize outcomes.
曲妥珠单抗辅助治疗 HER2+乳腺癌可降低复发和死亡率,自 2006 年以来一直是标准治疗方法。目的是分析真实世界中的健康结果。这是一项观察性、回顾性研究,纳入了过去 15 年中在西班牙仅一家中心接受过曲妥珠单抗辅助治疗的 HER2+乳腺癌 I-III 期患者。根据接受的曲妥珠单抗周期数和心脏毒性评估生存情况。在 1479 例患者中,有 275 例(18.60%)HER2 阳性患者接受了辅助(73%)或新辅助/辅助(26%)曲妥珠单抗治疗,联合(90%)或序贯(10%)化疗。5 年时总生存(OS)和无病生存(DFS)概率分别为 0.93(95%CI 0.89-0.96)和 0.88(95%CI 0.83-0.92)。有 54 例(19.64%)患者出现显著无症状左心室射血分数下降和心力衰竭,分别有 12 例(4.36%)患者出现心力衰竭。68 例(24.70%)患者接受了 16 个周期以下的治疗,尤其是年龄大于 65 岁(OR 0.371,95%CI 0.152-0.903;p=0.029)和有心脏毒性(OR 15.02,95%CI 7.437-30.335;p<0.001)的患者。心脏毒性的风险与接受放疗(OR 0.0362,95%CI 0.139-0.938;p=0.037)有关。高血压(HR 0.361,95%CI 0.151-0.863,p=0.022)、新辅助治疗(HR 0.314,95%CI 0.132-0.750,p=0.009)和心脏毒性(HR 2.755,95%CI 1.235-6.143,p=0.013)与 OS 显著相关。只有新辅助治疗与 DFS 显著相关(HR 0.437,95%CI 0.213-0.899,p=0.024)。新辅助和辅助曲妥珠单抗的有效性可被认为与临床试验相当。在真实世界中,应考虑年龄、高血压、放疗、新辅助治疗和心脏毒性等因素,以优化治疗效果。